Clinical Trials · NCT00104715
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- UNICANCER
- Enrollment
- 385
- Start date
- Oct 2004
- Locations
- 41 sites, France
- Primary endpoint
- Overall survival at 36 months